ReviewThe Journal of pharmacology and experimental therapeutics2025
A review of targeted drug delivery with antibody-drug complexes.
Review in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Enhancing diabetes treatment by targeted nucleic acid and drug delivery using cell-penetrating peptides, peptide nucleic acids, and receptor targeting.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Monoclonal antibodies are a versatile platform for targeted drug delivery. Their high specificity and favorable pharmacokinetics allow for selective drug delivery to targeted cells. A primary drug delivery application is antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic payloads via covalent linkers. While ADCs have shown remarkable clinical success, several limitations remain, including complex conjugation chemistries, heterogeneity in drug-to-antibody ratios, exposed hydrophobic patches, and off-target payload release, which can result in systemic toxicity. To complement existing ADC platforms and mitigate some of these issues, alternative formats referred to as antibody-drug complexes (ADCx) have been developed. ADCx are generated by forming reversible, high-affinity complexes between antibodies and drugs or preformed drug conjugates. This review discusses the ADCx formats reported to date, focusing on the unique advantages and potential limitations of each format. SIGNIFICANCE STATEMENT: Antibody-drug complexes offer a modular, noncovalent alternative to traditional antibody-drug conjugates. This review comprehensively evaluates antibody-drug complex formats, highlighting their potential to expand the utility of antibody-based drug delivery for next-generation therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.